Pharmacopeia, a US firm focused on the discovery and development of novel, small-molecule therapeutics, says it has identified two new lead compounds for advancement in its alliance with UK drug giant GlaxoSmithKline, through its collaboration with the latter's Center of Excellence for External Drug Discovery. The first of the lead compounds forms the basis of a new lead optimization program based on identifying a treatment for respiratory disease. The other newly-identified lead product is the second from a program in inflammatory pain. As a result, Pharmacopeia will receive milestone payments totaling $1.0 million from GSK.
$83M per program possible for US firm
Under the terms of the collaboration, Pharmacopeia has already received $10.0 million from GSK in connection with early discovery activities and is entitled to a further $5.0 million on the completion of additional early discovery activities (Marketletter July 23). The US firm is also entitled to success-based milestone payments totaling up to $83.0 million per program and potentially double-digit royalties on the sales of any product commercialized by GSK under the multi-program deal. Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia may independently pursue them, subject to its obligations to GSK under the accord.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze